avacopan
chemocentryx
['avacopan']
avacopan outcomes among pts w/baseline egfr &lt;20 identified early improvement in upcr, did not persist at 52wks (peculiar?). egfr also improved &amp; persisted at 52 weeks caveat: can't trust 52wk data from advocate! pts did not receive (current) standard of care #acr22 
MCW Rheumatologist | Internal Medicine APD | Rheumatology APD | Med Dir Vasculitis Program | Host, EBRheum Podcast | https://t.co/o4nOnziCiM | Newsletter: